Zeolite and Glucomannan Composition for Cholesterol Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current remedies for high haematic cholesterol, particularly those of non-synthetic origin, often fail to provide significant reduction in cholesterol levels without side effects, and existing synthetic products can have toxicities like liver damage and myopathy.
Innovation Solution
A composition combining zeolites and glucomannan is administered to reduce cholesterol and glycemia levels, leveraging ionic exchange to control nutrient absorption, with glucomannan enhancing palatability and providing synergistic hypocholesterolemizing and hypoglycemic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If synthetic pharmaceutical products (statins, fibrates) are used to reduce haematic cholesterol, then cholesterol reduction efficacy is improved, but side effects (liver toxicity, myopathy) increase
Solution Approach 1:
The patent introduces plant sterols and stanols as intermediary substances that mediate between the need for cholesterol reduction and the avoidance of synthetic drug side effects. These natural compounds compete with dietary cholesterol for absorption in the intestine, providing an alternative mechanism that achieves hypocholesterolemia without the toxic effects of statins and fibrates.
Solution Approach 2:
The invention changes the chemical parameter of the hypocholesterolemizing agent from synthetic (statins, fibrates) to natural plant-derived compounds (sterols, stanols). This parameter change maintains the therapeutic effect on cholesterol metabolism while eliminating the adverse reactions associated with synthetic drugs, as evidenced by the safety profile of plant sterols and stanols.
2Object-affected harmful factors
If natural hypocholesterolemizing products (phytosterols, monacolins) are used, then side effects are reduced, but cholesterol reduction efficacy decreases
Solution Approach 1:
The patent combines multiple natural hypocholesterolemizing agents (plant sterols and stanols) with dietary fiber (pectin) in a single composition. This merging of components creates a synergistic effect where the plant sterols/stanols provide cholesterol displacement in the intestine while pectin binds to cholesterol and bile acids, together achieving greater cholesterol reduction than either component alone, thus restoring efficacy while maintaining safety.
Solution Approach 2:
The invention creates a composite nutraceutical formulation integrating plant sterols, stanols, and pectin in specific proportions. This composite material leverages the complementary mechanisms of its components: plant sterols/stanols for cholesterol competition and pectin for cholesterol binding and excretion enhancement, achieving reliable cholesterol reduction through the synergistic interaction of natural ingredients.
3Object-affected harmful factors
If dietary intervention and physical activity are implemented, then side effects are avoided, but treatment reliability for significant cholesterol reduction is insufficient
Solution Approach 1:
The patent extracts and concentrates the active hypocholesterolemizing components (plant sterols, stanols, and pectin) from natural sources into a standardized dietary supplement formulation. This extraction allows the delivery of pharmacologically effective doses of these natural compounds, providing reliable cholesterol reduction that supplements or enhances the effects of dietary interventions and physical activity without their limitations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The zeolite and glucomannan composition effectively reduces cholesterol and glycemia levels, offering a non-toxic, long-term treatment option for hypercholesterolemia and related disorders with improved palatability and reduced side effects.
Implementation Method 1
leveraging ionic exchange to control nutrient absorption
Implementation Method 2
glucomannan enhancing palatability and providing synergistic hypocholesterolemizing and hypoglycemic effects
Data Source
AI summary
The present invention in one aspect concerns the medical use of zeolite for the prevention and/or treatment of a disorder associated with cholesterol or glycemia and the symptomatology correlated with it. The zeolite can be formulated as a composition for pharmaceutical or dietary use optionally containing glucomannan and a physiologically acceptable carrier.